Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTX-M-15

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3568-3575

  Pouillot, Flavie ^b   Chomton, Maryline ^a   Blois, Hélène ^b   Courroux, Celine ^a   Noelig, Julien ^b   Bidet, Philippe ^a   Bingen, Edouard ^a   Bonacorsi, Stéphane ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Pherecydes Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; BETA LACTAMASE CTX M 15; ESCHERICHIA COLI 200 PP; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; BACTERIUM ISOLATE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG TISSUE LEVEL; ESCHERICHIA COLI; EX VIVO STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY; MENINGITIS; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; SPLEEN; SURVIVAL;

ANIMALS; BACTERIOPHAGES; BETA-LACTAMASES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MENINGITIS; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS;

EID: 84862575217     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06330-11     Document Type: Article

References (46)

1. Barrow P, Lovell M, Berchieri A, Jr. 1998. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin. Diagn. Lab. Immunol. 5:294-298.
2. Bidet P, et al. 2007. Combined multilocus sequence typing and o serogrouping distinguishes Escherichia coli subtypes associated with infant urosepsis and/or meningitis. J. Infect. Dis. 196:297-303.
3. Birgy A, et al. 2011. Early detection of colonization by VIM-1-producing Klebsiella pneumoniae and NDM-1-producing Escherichia coli in two children returning to France. J. Clin. Microbiol. 49:3085-3087.
4. Bonacorsi S, et al. 2003. Molecular analysis and experimental virulence of French and North American Escherichia coli neonatal meningitis isolates; identification of new virulent clone. J. Infect. Dis. 187:1895-1906.
5. Boyer-Mariotte S, et al. 2008. CTX-M-15-producing Escherichia coli in fatal neonatal meningitis: failure of empirical chemotherapy. J. Antimicrob. Chemother. 62:1472-1474.
6. Bruttin A, Brussow H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49:2874-2878.
7. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA. 2002. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2:35. doi:10.1186/1471-2180-2-35.
8. Capparelli R, et al. 2010. Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy. J. Infect. Dis. 201:52-61.
9. Capra ML, Quiberoni A, Reinheimer J. 2006. Phages of Lactobacillus casei/paracasei: response to environmental factors and interaction with collection and commercial strains. J. Appl. Microbiol. 100:334-342.
10. Carey-Smith GV, Billington C, Cornelius AJ, Hudson JA, Heinemann JA. 2006. Isolation and characterization of bacteriophages infecting Salmonella spp. FEMS Microbiol. Lett. 258:182-186.
11. Carmody LA, et al. 2010. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 201:264-271.
12. Chibani-Chennoufi S, et al. 2004. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob. Agents Chemother. 48:2558-2569.
13. Chow JJ, Batt CA, Sinskey AJ. 1988. Characterization of Lactobacillus bulgaricus bacteriophage ch2. Appl. Environ. Microbiol. 54:1138-1142.
14. Clermont O, et al. 2008. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Chemother. 61:1024-1028.
15. Debarbieux L, et al. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201:1096-1104.
16. Dubois D, et al. 2009. CTX-M beta-lactamase production and virulence of Escherichia coli K1. Emerg. Infect. Dis. 15:1988-1990.
17. Dubos RJ, Straus JH, Pierce C. 1943. The multiplication of bacteriophage in vivo and its protective effect against an experimental infection with Shigella Dysenteriae. J. Exp. Med. 78:161-168.
18. Gaschignard J, et al. 2011. Neonatal bacterial meningitis: 444 cases in 7 years. Pediatr. Infect. Dis. J. 30:212-217.
19. Geier MR, Trigg ME, Merril CR. 1973. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246:221-223.
20. Houdouin V, et al. 2008. Association between mortality of Escherichia coli meningitis in young infants and non-virulent clonal groups of strains. Clin. Microbiol. Infect. 14:685-690.
21. Houdouin V, et al. 2008. Clinical outcome and bacterial characteristics of 99 Escherichia coli meningitis in young infants. Arch. Pediatr. 15(Suppl 3):S138-S147.
22. Houdouin V, et al. 2002. A uropathogenicity island contributes to the pathogenicity of Escherichia coli strains that cause neonatal meningitis. Infect. Immun. 70:5865-5869.
23. Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N. 2011. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob. Agents Chemother. 55:1358-1365.
24. Kim KS. 1985. Comparison of cefotaxime, imipenem-cilastatin, ampicil-lingentamicin, and ampicillin-chloramphenicol in the treatment of experimental Escherichia coli bacteremia and meningitis. Antimicrob. Agents Chemother. 28:433-436.
25. Kim KS, et al. 1992. The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat. J. Clin. Invest. 90:897-905.
26. Kim KS, Manocchio M, Bayer AS. 1984. Efficacy of cefotaxime and latamoxef for Escherichia coli bacteremia and meningitis in newborn rats. Chemotherapy 30:262-269.
27. Kutter E, et al. 2010. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11:69-86.
28. Lassiter HA, Watson SW, Seifring ML, Tanner JE. 1992. Complement factor 9 deficiency in serum of human neonates. J. Infect. Dis. 166:53-57.
29. Mahjoub-Messai F, et al. 2011. Escherichia coli isolates causing bacteremia via gut translocation and urinary tract infection in young infants exhibit different virulence genotypes. J. Infect. Dis. 203:1844-1849.
30. Mariani-Kurkdjian P, et al. 1999. Bacterial concentration in the cerebrospinal fluid in childhood meningitis. Presse Med. 28:1227-1230.
31. McVay CS, Velasquez M, Fralick JA. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51:1934-1938.
32. Merabishvili M, et al. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944. doi:10.1371/journal.pone.0004944.
33. Merril CR, et al. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. U. S. A. 93:3188-3192.
34. Moissenet D, et al. 2010. Meningitis caused by Escherichia coli producing TEM-52 extended-spectrum beta-lactamase within an extensive outbreak in a neonatal ward: epidemiological investigation and characterization of the strain. J. Clin. Microbiol. 48:2459-2463.
35. Nicolas-Chanoine MH, et al. 2008. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother. 61:273-281.
36. Nishikawa H, et al. 2008. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections. Arch. Virol. 153:507-515.
37. Postic B, Finland M. 1961. Observations on bacteriophage typing of Pseudomonas aeruginosa. J. Clin. Invest. 40:2064-2075.
38. Scheld M. 1986. Experimental animal models of bacterial meningitis, p 139-186. In Zak O, SandsMA(ed), Experimental models in antimicrobial chemotherapy, vol. 1. Academic Press, New York, NY.
39. Sherwood L. 2006. Blood vessel and arterial tension, p 286. In Boeck D (ed), Human physiology, 2nd ed. Thomson Brooks/Cole, Belmont, CA.
40. Smith HW, Huggins MB. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318.
41. Stenholm AR, Dalsgaard I, Middelboe M. 2008. Isolation and characterization of bacteriophages infecting the fish pathogen Flavobacterium psychrophilum. Appl. Environ. Microbiol. 74:4070-4078.
42. Toussaint AJ, Muschel LH. 1959. Neutralization of bacteriophage by normal serum. Nature 183:1825-1827.
43. Wang J, et al. 2006. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int. J. Mol. Med. 17:347-355.
44. Watanabe R, et al. 2007. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51:446-452.
45. Weber-Dabrowska B, Mulczyk M, Gorski A. 2003. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant. Proc. 35:1385-1386.
46. Yang H, Liang L, Lin S, Jia S. 2010. Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii. BMC Microbiol. 10:131. doi:10.1186/1471-2180-10-131.